Objective: This study aims to investigate the effect of Kinglong capsules in malignant tumor patients with hypercoagulable state. Methods: A total of 106 malignant tumor patients with hypercoagulable state were divided into the observation (G1) and control groups (G2). In Gl, 53 patients started taking the Kinglong capsules (1.0 g each time, 3 times a day) after their first chemotherapy cycle, until the beginning of next chemotherapy cycle. In G2, the other 53 patients took chemotherapy only. The value of PLT(platelet), Fib(Fibrinogen), PT(prothrombin time), APTT(activated partial thrombopoastin time), and D-D(D-dimer) for each patient was detected before the initial and the next cycle of chemotherapy. The value of PLT, Fib, PT, APTT, and D-D in the two groups was analyzed using statistical methods. The efficacy was evaluated after two cycles of chemotherapy; adverse reactions were evaluated after each cycle. Result: The time of PT and APTT was prolonged (P=0.021) significantly, and the value of PLT, Fib, and D-D decreased (P=0.043) significantly after treatment with Kinglong capsules. The short-term therapeutic efficacy was not statistically significant (P=0.073) between the two groups. Moreover, the Ⅲ - Ⅳdegree of neutropenia was significantly lower in the observation group than the control group (P=0.042). Conclusion: The results of chemotherapy combined with Kinglong capsules can prolong the PT and APTT time and reduce the value of PLT, Fib, and D-D significantly, thereby improving the hypercoagulable state in malignant tumor patients.%目的:观察金龙胶囊对恶性肿瘤化疗患者高凝状态的影响.方法:将106例恶性肿瘤合并高凝状态患者随机分为观察组及对照组,观察组53例在化疗的基础上同时服用金龙胶囊,每次4粒(1.0 g),一日3次,至下周期化疗开始；对照组53例单纯采用化疗.两组患者每周期化疗前及下周期化疗前检测PLT、Fib、PT、APTT、D-D；两组患者每完成2个周期化疗后进行疗效评价,每周期化疗后评价化疗不良反应.结果:观察组治疗后PT、APTT较对照组治疗后显著延长(P＜0.05),PLT、Fib、D-D较对照组治疗后明显降低(P＜0.05)；观察组和对照组近期疗效差异无统计学意义(P=0.073)；观察组Ⅲ～Ⅳ度中性粒细胞减少发生率明显低于对照组(P=0.042).结论:恶性肿瘤患者化疗同时服用金龙胶囊可延长患者PT、APTT,降低PLT、Fib、D-D水平,从而改善化疗患者的高凝状态.
展开▼
